MBIO Stock - Mustang Bio, Inc.
Unlock GoAI Insights for MBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-2,225,000 | $-3,031,000 | $-2,306,000 | $-1,785,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,245,000 | $-50,726,000 | $-76,159,000 | $-66,723,000 | $-56,806,000 |
| Net Income | $-15,752,000 | $-51,602,000 | $-77,525,000 | $-66,370,000 | $-60,015,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.57 | $-6.00 | $-11.25 | $-11.40 | $-17.10 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Visit WebsiteEarnings History & Surprises
MBIOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-0.07 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-0.19 | — | — |
Q2 2025 | May 14, 2025 | — | $-0.05 | — | — |
Q1 2025 | Mar 24, 2025 | $-5.50 | $-37.95 | -590.0% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-6.50 | $-2.00 | +69.2% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-7.00 | $-12.00 | -71.4% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.87 | $-23.00 | -2543.7% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-84.00 | $-35.50 | +57.7% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-94.00 | $-61.50 | +34.6% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-103.50 | $-100.00 | +3.4% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-142.50 | $-103.00 | +27.7% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-142.43 | $-134.93 | +5.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-149.93 | $-134.93 | +10.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-157.42 | $-142.43 | +9.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-134.93 | $-149.93 | -11.1% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-157.42 | $-164.92 | -4.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-134.93 | $-142.43 | -5.6% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-149.93 | $-119.94 | +20.0% | ✓ BEAT |
Q2 2021 | May 14, 2021 | $-149.93 | $-142.43 | +5.0% | ✓ BEAT |
Frequently Asked Questions about MBIO
What is MBIO's current stock price?
What is the analyst price target for MBIO?
What sector is Mustang Bio, Inc. in?
What is MBIO's market cap?
Does MBIO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MBIO for comparison